On August 6, 2026 Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, reported that it has been selected for an oral presentation at the European Society of Gene and Cell Therapy annual meeting in Hamburg, Germany, 27-30 October 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ESGCT Annual Meeting is the leading gene and cell therapy conference in Europe and the second largest globally, recognized as one of the most prestigious scientific meetings in the field. The meeting is widely attended by pharma industry professionals, academics, patient advocacy organizations and life science media. Only a small number of submitted abstracts are selected for oral presentation, underscoring the scientific quality and relevance of the work presented.

"ESGCT is one of the most important international meetings in the gene and cell therapy field, and it is very important for Circio that the organizing committee has selected one of Circio´s abstracts for an oral presentation," said Dr. Thomas B Hansen, CTO of Circio. "Presenting our circVec platform at ESGCT provides an excellent opportunity to showcase how our proprietary DNA vector technology has the potential to significantly enhance next-generation gene and cell therapies to a highly relevant audience of life science and industry leaders. This meeting also provides an important forum to engage with existing and prospective collaborators and partners as we continue to advance our R&D programs and expand commercial opportunities."

Circio has submitted three abstracts for ESGCT 2026, of which one has been selected for oral presentation and two for poster presentation. Further information about the Circio presentations and the full abstract texts will be released on the general abstract publication date, 27 October 2026.

Presentation title: circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies

Session: Non-viral vectors/nanotechnology and RNA therapeutics I

Time & location: Wednesday 28 October at 10:00am – Hamburg, Germany

(Press release, Circio, AUG 6, 2026, View Source [SID1234669740])

On August 5, 2026 BeOne Medicines reported second quarter 2026 results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, BeOne Medicines, AUG 5, 2026, View Source [SID1234670745])

On August 5, 2026 Astellas reported Financial Results for Three Months Ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Astellas, AUG 5, 2026, View Source [SID1234670604])

On August 5, 2026 Synthekine, Inc., a clinical-stage biotechnology company developing precision cytokine therapeutics, reported the appointment of Susan M. Molineaux, Ph.D., as Chief Executive Officer. Dr. Molineaux brings more than 20 years of C-level biotechnology leadership experience to Synthekine as the company continues to advance STK-012, an engineered α/β-biased IL-2 partial agonist, into late-stage clinical development in non-small cell lung cancer (NSCLC). Dr. Molineaux succeeds Debanjan Ray, who has served as CEO since the company’s founding and will continue to serve as an advisor to Synthekine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"On behalf of the board, I am delighted to welcome Susan as CEO," said John Orwin, Chairman of Synthekine. "Her experience and leadership in late-stage oncology drug development will be critical in guiding Synthekine through its next stage of growth."

"I’m honored to join Synthekine at a pivotal moment for the company," said Dr. Molineaux. "Debanjan and the team have built something remarkable – a deep scientific platform and a clear path forward with STK-012. I’m excited to help guide Synthekine through late-stage clinical development and bring a new option to a population of NSCLC patients who face limited treatment choices today."

Dr. Molineaux brings broad leadership experience in the biopharmaceutical industry and has extensive experience guiding companies through clinical development. Previously, she served as CEO and co-founder of Para Therapeutics, Inc., from April 2023 to July 2025. Before this, Dr. Molineaux was CEO and President of Calithera Biosciences, Inc., which she co-founded in June 2010, took public in 2014, and led until March 2023. Prior to this, she co-founded Proteolix in December 2003 and served first as its Chief Scientific Officer and then as CEO. Proteolix was acquired by Onyx Pharmaceuticals, Inc., in November 2009.

Previously, Dr. Molineaux held multiple senior management positions in biopharmaceutical companies, including Vice President of Biology at Rigel Pharmaceuticals, Inc., Vice President of Biology at Praelux, Inc., and Vice President of Drug Development at Praecis Pharmaceuticals, Inc. She currently serves as a Scientific Advisor to Lightstone Ventures, a private life sciences investment company. Dr. Molineaux also brings considerable board experience to Synthekine. She is currently the Executive Chair of Seranova Bio, Inc. and a member of the board at Geron Corporation. She has also served on the boards of Repare Therapeutics, Inc., Cyteir Therapeutics, Inc., and Theravance Biopharma, Inc. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.

"The board and I would also like to thank Debanjan for his many accomplishments from founding Synthekine and leading the company over the past seven years," continued Mr. Orwin. "Starting from Synthekine’s formation, he has built the company from its earliest stages of research and has continued its momentum through the advancement of STK-012 into a global, randomized Phase 2 study. His leadership and vision have been instrumental in Synthekine’s success, and we wish him the very best."

"It has been a privilege to lead Synthekine and help turn an ambitious scientific vision into real medicines for patients," said Mr. Ray. "Together, we pioneered new approaches to cytokine engineering, forged partnerships with leading pharmaceutical companies, and advanced STK-012 into a randomized Phase 2 study. I look forward to supporting a smooth transition and watching this team continue to redefine what cytokine therapeutics can do."

(Press release, Synthekine, AUG 5, 2026, View Source [SID1234670271])

On August 5, 2026 CellFiber Co., Ltd. ("CellFiber"), a Tokyo-based biotechnology company built on its proprietary CellFiber cell encapsulation platform, and Tidewave Bio ("Tidewave"), a Los Angeles-based biotechnology company developing a universal, off-the-shelf immunotherapy platform for solid tumors, reported a collaboration to evaluate CellFiber’s closed, automated 3D cell culture platform in support of the scalable manufacturing of Tidewave’s next-generation cell immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the collaboration, the parties have agreed to undertake a joint proof-of-concept evaluation comparing conventional planar (2D) cell culture against CellFiber’s encapsulation (3D) approach for the expansion and differentiation of immune cells relevant to Tidewave’s allogeneic platform. The work, to be conducted at CellFiber’s facility in Tokyo, is designed to generate process performance data that will drive Tidewave’s manufacturing strategy as the program advances, while demonstrating the applicability of the CellFiber platform to off-the-shelf solid tumor immunotherapy manufacturing. Any further activities beyond the proof-of-concept evaluation will be subject to separate written agreement between the parties.

"Tidewave Bio’s mission is to make next-generation cancer immunotherapy accessible to every solid tumor patient, regardless of tumor type, treatment setting, or geography," said Francois Binette, Chief Executive Officer of Tidewave Bio. "Delivering on that mission requires manufacturing approaches that can scale efficiently, reliably, and cost-effectively. We are pleased to partner with CellFiber to evaluate how their innovative encapsulation platform can support our process development strategy as we advance toward the clinic."

"Tidewave Bio is pursuing a genuinely differentiated approach to solid tumor immunotherapy, and we are excited to support their program," said Dr. Kazuchika Furuishi, Representative Director and Chief Executive Officer of CellFiber. "Our CellFiber platform was designed to remove the manufacturing bottlenecks that have historically constrained cell therapy scale-up. This collaboration is an opportunity to demonstrate the value our closed, automated 3D culture system can bring to the next generation of off-the-shelf cell therapies, and to advance our shared vision of making these therapies more widely accessible to patients."

(Press release, Tidewave Bio, AUG 5, 2026, View Source [SID1234669762])